Novo Nordisk reported strong demand for its Wegovy pill, which launched in the U.S. in January, with about 50,000 prescriptions filled weekly and over 170,000 users already. Most prescriptions are for the starter dose and paid out of pocket. The pill, priced at $149 a month, is more accessible than the $349 injectable version and may attract patients previously using compounded drugs. Experts believe Wegovy not only aids in weight loss but also reduces heart disease risk, enhancing its appeal.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
